Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products and Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, announced an  Exclusive License Agreement in Asia-Pacific  [April 25, 2018].   Entasis’ ETX2514 is a novel broad-spectrum intravenous inhibitor of β-lactamases, which are a major cause of antibiotic … Continue reading Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific